Here are four highlights:
1. The company’s AmnioFix and EpiFix are among the products listed.
2. The certificate stated MiMedx human cells, tissues and cellular and tissue-based products may be marketed in and legally exported from the United States.
3. It also states that in the last inspection the plants at that time appeared to be in compliance with FDA regulation.
4. MiMedx is an integrated developer, processor and marketer of patent protected proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues.
More articles on devices and implants:
FDA approves InVivo’s Neuro-Spinal Scaffold study as ‘pivotal probable benefit’ — 5 key notes
Benvenue Medical obtains $60M financing: 5 things to know
Agent Medical launches 2 lower extremity devices: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
